Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomics

13 May 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

IntroductionMetastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) that is not amenable to local therapy is treated with programmed death-1 (PD-1) inhibitors. Although response rates are relatively high, there are no validated predictive biomarkers to guide treatment.
As a result, a subset of patients — particularly frail and elderly patients which can be treated with local palliative therapy — are exposed to immune-related adverse events without clinical benefit. Here, we present a retrospective evaluation of ENLIGHT-DP, a novel digital pathology biomarker which predicts response to PD-1 inhibition in advanced cSCC directly from histopathology slides using inferred transcriptomics.
Methods. We scanned high-resolution hematoxylin and eosin (H&E) slides from pretreatment tumor samples of 38 patients with advanced cSCC treated with cemiplimab and retrospectively generated an individualized prediction score using the ENLIGHT-DP pipeline in a two-step process: (i) inference of mRNA expression profiles directly from H&E slides using the DeepPT deep-learning algorithm, and (ii) integration of these inferred transcriptomes into ENLIGHT, a transcriptomics-based precision oncology platform that predicts therapeutic response.

Clinical Editorial

Summary

Frontiers in Immunology published a clinical update in Infectious Disease on 13 May 2026.

The item focuses on Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomics.

Review the original article for the full source wording and details.